Sacubitril/Valsartan Contraindications
Sacubitril/valsartan is absolutely contraindicated in patients with: hypersensitivity to any component, history of angioedema related to previous ACE inhibitor or ARB therapy, concomitant use with ACE inhibitors (must wait 36 hours after last ACE inhibitor dose), concomitant use of aliskiren in patients with diabetes, pregnancy, and severe hepatic impairment (Child-Pugh C). 1, 2
Absolute Contraindications
The FDA label and ACC/AHA guidelines clearly define the following as absolute contraindications 2, 1:
- Hypersensitivity to sacubitril, valsartan, or any component of the formulation
- History of angioedema related to previous ACE inhibitor or ARB therapy
- Concomitant ACE inhibitor use - requires a mandatory 36-hour washout period between stopping an ACE inhibitor and starting sacubitril/valsartan to minimize angioedema risk 2, 3
- Concomitant aliskiren use in patients with diabetes
- Pregnancy - causes fetal toxicity through effects on the renin-angiotensin system during second and third trimesters 2
- Severe hepatic impairment (Child-Pugh C classification) 1
Critical Cautions Requiring Dose Adjustment or Close Monitoring
While not absolute contraindications, these conditions require careful consideration and often dose modification 1, 2:
Renal Impairment
- Severe renal impairment (eGFR <30 mL/min/1.73 m²): Start at half the usual dose (24/26 mg twice daily in adults), then uptitrate as tolerated 1, 2
- Mild-to-moderate impairment (eGFR 30-59): No starting dose adjustment required
- Important caveat: Recent evidence suggests continuation of sacubitril/valsartan may be safe even when eGFR deteriorates below 30 mL/min/1.73 m² in patients already on therapy 4
Hepatic Impairment
- Moderate hepatic impairment (Child-Pugh B): Start at half the usual dose (24/26 mg twice daily), then uptitrate 1, 2
- Mild impairment (Child-Pugh A): No adjustment needed
Hypotension
- Systolic blood pressure <100 mm Hg: Use with caution; volume- or salt-depleted patients are at greater risk 1, 2
- Correct volume depletion before initiation or start at lower dose
- Monitor closely and adjust concomitant antihypertensives as needed
Other Important Cautions
- Volume depletion: Correct before starting therapy 1
- Renal artery stenosis: Use with caution 1
- Hyperkalemia risk: Monitor potassium levels, especially when combined with other RAAS inhibitors or MRAs 1, 5
- Lactation: No data available; use caution 1
Angioedema Risk - A Critical Safety Concern
Angioedema occurs at comparable rates to ACE inhibitors despite the ARB component, with significantly higher risk in Black patients. 6 The neprilysin inhibition component maintains angioedema risk similar to ACE inhibitors. If angioedema occurs, discontinue immediately and do not re-administer 2. Patients with hereditary angioedema should not receive this medication 2.
Common Pitfalls to Avoid
- Starting too soon after ACE inhibitor: Always observe the mandatory 36-hour washout to prevent dual RAAS blockade and increased angioedema risk 2
- Combining with other RAAS inhibitors: Never add an ACE inhibitor or additional ARB to patients on sacubitril/valsartan 3
- Ignoring baseline blood pressure: Patients with borderline systolic BP require careful monitoring and may need lower starting doses 1
- Inadequate monitoring: Check blood pressure, electrolytes, and renal function shortly after initiation and periodically thereafter 1